An approved pilot study is underway that explores the impact of wearing two Fos Biomedical Viral Response devices in combination with orally administered Copper Glycinate (2mg BID) on reducing infectious markers of the blood and antibody markers for COVID-19. In addition a small number of questionnaires will be administered. It is believed that the combination of this particular form of light therapy in conjunction with copper ions will produce an antiviral effect.

A sample of convenience of up to 40 subjects with the goal of 30 subjects completing made up of both men and women aged 18-70 who are first responders will be selected to participate. Due to the severity of the COVID-19 outbreak this will be an open label trial with no control group